QOL ANALYSIS FROM NEJ 002 STUDY COMPARING GEFITINIB TO CHEMOTHERAPY FOR NON-SMALL CELL LUNG CANCER WITH MUTATED EGFR

被引：0
|
作者：
Yoshizawa, H. [1 ]
Kobayashi, K. [2 ]
Inoue, A. [3 ]
Maemondo, M. [4 ]
Sugawara, S. [5 ]
Oizumi, S. [6 ]
Gemma, A. [7 ]
Morita, S. [8 ]
Hagiwara, K.
Nukiwa, T. [9 ]
机构：
[1] Niigata Univ, Med & Dent Hosp, Biosci Med Res Ctr, Niigata, Japan
[2] Saitama Med Univ, Int Med Ctr, Dept Resp Oncol, Saitama, Japan
[3] Tohoku Univ Hosp, Sendai, Miyagi, Japan
[4] Miyagi Canc Ctr, Dept Resp Med, Natori, Miyagi, Japan
[5] Sendai Kosei Hosp, Dept Resp Med, Sendai, Miyagi, Japan
[6] Hokkaido Univ, Sch Med, Dept Med 1, Sapporo, Hokkaido 060, Japan
[7] Nippon Med Sch, Dept Internal Med, Tokyo 113, Japan
[8] Yokohama City Univ, Med Ctr, Dept Biostat & Epidemiol, Yokohama, Kanagawa 232, Japan
[9] Tohoku Univ, Inst Dev Aging & Canc, Dept Resp Oncol & Mol Med, Sendai, Miyagi 980, Japan
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：122 / 122
页数：1
相关论文
共 50 条
  • [1] Update analysis of NEJ009: Gefitinib alone (G) versus gefitinib plus chemotherapy (GCP) for non-small cell lung cancer with mutated EGFR.
    Miyauchi, Eisaku
    Morita, Satoshi
    Nakamura, Atsushi
    Hosomi, Yukio
    Watanabe, Kana
    Ikeda, Satoshi
    Seike, Masahiro
    Fujita, Yuka
    Minato, Koichi
    Ko, Ryo
    Harada, Toshiyuki
    Hagiwara, Koichi
    Kobayashi, Kunihiko
    Nukiwa, Toshihiro
    Inoue, Akira
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated EGFR
    Miyauchi, Eisaku
    Morita, Satoshi
    Nakamura, Atsushi
    Hosomi, Yukio
    Watanabe, Kana
    Ikeda, Satoshi
    Seike, Masahiro
    Fujita, Yuka
    Minato, Koichi
    Ko, Ryo
    Harada, Toshiyuki
    Hagiwara, Koichi
    Kobayashi, Kunihiko
    Nukiwa, Toshihiro
    Inoue, Akira
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (31) : 3587 - +
  • [3] Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
    Maemondo, Makoto
    Inoue, Akira
    Kobayashi, Kunihiko
    Sugawara, Shunichi
    Oizumi, Satoshi
    Isobe, Hiroshi
    Gemma, Akihiko
    Harada, Masao
    Yoshizawa, Hirohisa
    Kinoshita, Ichiro
    Fujita, Yuka
    Okinaga, Shoji
    Hirano, Haruto
    Yoshimori, Kozo
    Harada, Toshiyuki
    Ogura, Takashi
    Ando, Masahiro
    Miyazawa, Hitoshi
    Tanaka, Tomoaki
    Saijo, Yasuo
    Hagiwara, Koichi
    Morita, Satoshi
    Nukiwa, Toshihiro
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (25): : 2380 - 2388
  • [4] FIRST-LINE GEFITINIB VS CARBOPLATIN/PACLITAXEL IN NON-SMALL CELL LUNG CANCER WITH EGFR MUTATION: PHASE III STUDY NEJ002
    Osamu, Ishimoto
    Kobayashi, Kunihiko
    Inoue, Akira
    Maemondo, Makoto
    Sugawara, Shunichi
    Oizumi, Satoshi
    Saijo, Yasuo
    Gemma, Akihiko
    Morita, Satoshi
    Hagiwara, Koichi
    Nukiwa, Toshihiro
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 11 - 11
  • [5] Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer - data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002)
    Miyauchi, Eisaku
    Inoue, Akira
    Kobayashi, Kunihiko
    Maemondo, Makoto
    Sugawara, Shunichi
    Oizumi, Satoshi
    Isobe, Hiroshi
    Gemma, Akihiko
    Saijo, Yasuo
    Yoshizawa, Hirohisa
    Hagiwara, Koichi
    Nukiwa, Toshihiro
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2015, 45 (07) : 670 - 676
  • [6] GEFITINIB FOR NON-SMALL CELL LUNG CANCER (NSCLC) WITH MINOR EGFR MUTATIONS: A RETROSPECTIVE STUDY FROM THE NORTH EAST JAPAN STUDY GROUP (NEJ)
    Watanabe, S.
    Yoshizawa, H.
    Maemondo, M.
    Inoue, A.
    Sugawara, S.
    Isobe, H.
    Harada, M.
    Ishii, Y.
    Hagiwara, K.
    Kobayashi, K.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 413 - 413
  • [7] Quality of Life with Gefitinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: Quality of Life Analysis of North East Japan Study Group 002 Trial
    Oizumi, Satoshi
    Kobayashi, Kunihiko
    Inoue, Akira
    Maemondo, Makoto
    Sugawara, Shunichi
    Yoshizawa, Hirohisa
    Isobe, Hiroshi
    Harada, Masao
    Kinoshita, Ichiro
    Okinaga, Shoji
    Kato, Terufumi
    Harada, Toshiyuki
    Gemma, Akihiko
    Saijo, Yasuo
    Yokomizo, Yuki
    Morita, Satoshi
    Hagiwara, Koichi
    Nukiwa, Toshihiro
    [J]. ONCOLOGIST, 2012, 17 (06): : 863 - 870
  • [8] Miliary EGFR mutated non-small cell lung cancer
    Nguyen, Mike M.
    Moore, Melissa M.
    [J]. MEDICAL JOURNAL OF AUSTRALIA, 2021, 214 (03) : 118 - 118
  • [9] Interstitial Lung Disease Associated with Gefitinib in Japanese Patients with EGFR-mutated Non-small-cell Lung Cancer: Combined Analysis of Two Phase III Trials (NEJ 002 and WJTOG 3405)
    Akamatsu, Hiroaki
    Inoue, Akira
    Mitsudomi, Tetsuya
    Kobayashi, Kunihiko
    Nakagawa, Kazuhiko
    Mori, Keita
    Nukiwa, Toshihiro
    Nakanishi, Yoichi
    Yamamoto, Nobuyuki
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2013, 43 (06) : 664 - 668
  • [10] Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study
    Yuta Nio
    Hiroo Ishida
    Natsumi Matsumoto
    Sojiro Kusumoto
    Yutaro Kubota
    Takuya Tsunoda
    Yasutsuna Sasaki
    Ken-ichi Fujita
    [J]. BMC Pulmonary Medicine, 22
12345